Lakefront Biotherapeutics (LKFT) Receivables - Net (2014 - 2026)

Lakefront Biotherapeutics (LKFT) has 13 years of Receivables - Net data on file, last reported at $25.4 million in Q1 2026.

• Receivables - Net for Q1 2026 came in at $25.4 million, down 52.7% year-over-year; the trailing twelve-month figure through Mar 2026 was $25.4 million (down 52.7% YoY), and the FY2025 annual result was $24.1 million, down 52.49% from the prior year.
• Receivables - Net advanced to $25.4 million in Q1 2026 per LKFT's latest filing, from $24.1 million in the prior quarter.
• Over five years, Receivables - Net peaked at $69.2 million in Q1 2022 and troughed at $24.1 million in Q4 2025.
• A 5-year average of $47.4 million and a median of $50.7 million in 2024 frame the typical range for Receivables - Net.
• The sharpest annual moves came in 2022 and 2024: Receivables - Net tumbled 67.61% in 2022, then surged 65.74% in 2024.
• A 5-year view of Receivables - Net shows it stood at $41.2 million in 2022, then dropped by 25.79% to $30.6 million in 2023, then surged by 65.74% to $50.7 million in 2024, then slumped by 52.49% to $24.1 million in 2025, then gained by 5.59% to $25.4 million in 2026.
• Business Quant data shows LKFT's Receivables - Net at $25.4 million in Q1 2026, $24.1 million in Q4 2025, and $53.0 million in Q3 2025.